Dahua Technology Unveils Full-color Cube to Explore New Possibilities of Innovation
19.4.2023 15:45:00 EEST | Business Wire | Press release
Dahua Technology, a world-leading video-centric AIoT solution and service provider, unveils the 2023 Full-color Cube concept —— a cube of color magic that combines Full-color, Smart Dual Light and other technologies into infinite possibilities of innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005078/en/
For years, Dahua has been investing in Full-color Technology that assures users 24/7 colorful monitoring as well as trust-worthy performance in terms of clarity, definition, flexibility, accuracy and intelligence. This year, meet Full-color Cube! It integrates Full-color and Smart Dual Light with other technologies, creating infinite possibilities for innovation and allowing you to do more than you could ever imagine. (Photo: Business Wire)
“Dahua’s Full-color technology is continuously being upgraded, with the addition of Smart Dual Light as one great example. This year, we combined these two core technologies with AI, Duo and PT cameras, as well as other technologies to offer the Full-color Cube that further addresses users’ monitoring needs for vivid and color images in low-light environments,” said Eaden Xie, Product Manager at Dahua Technology.
Featuring panoramic vision, more personalized and flexible settings, intelligence at will, and future growth, the Full-color Cube unlocks a wealth of cutting-edge security functions through strong technological combinations.
Full-color + Panoramic: seamless 180° wide-angle image
The Full-color Panoramic series achieves a wider range of vision coverage by utilizing the capabilities of both Full-color Duo and PT cameras.
- Full-color + Duo
Based on Dahua’s advanced pixel-level metadata fusion algorithm, Full-color Duo camera adopts Dual F1.0 Aperture Lens and Dual 1/1.8" CMOS Sensors to create better imaging effects in low-light conditions. Compared with traditional cameras, its seamless 180° image significantly saves equipment and installation costs. Also, the eyeball model supports 3-axis rotation, which makes installation and operation more convenient. Moreover, its EPTZ function features panoramic image with multiple target details.
- Full-color + PT
Equipped with larger pan & tilt angle, Full-color PT camera provides an expanded field of view with fewer blind spots, while capturing 24/7 color images for more information and details. A variety of mounting brackets makes it easy to install on a pole, ceiling, or wall.
TiOC: full-time protection before, during, and after an event
TiOC (Three-in-One Camera) is a star product of the Dahua Full-color family that integrates Smart Dual Light, Active Deterrence, and AI. Before the event, SMD 4.0 and Perimeter Protection technology accurately focuses on human and vehicle alarms. During the event, Smart Dual Light technology records events in color, while actively deterring intruders with red and blue lights and siren. After the event, Smart Search quickly retrieves target footages, reducing investigation time. TiOC also allows third-party platform access for live broadcast/playback, video and audio parameter configuration, etc.
For more details about Full-color Cubes, please visit here .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005078/en/
Contact information
Zoe Xu (xu_shuyi@dahuatech.com )
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom